The “Global Cell Line Development Market 2017-2021” report has been added to Research and Markets’ offering.
The global cell line development market to grow at a CAGR of 12.27% during the period 2017-2021.
The report, Global Cell Line Development Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
One trend in the market is increase demand for regenerative medicine. Regenerative medicine, a branch of medicine develops process to regrow, repair and replace damaged and diseased cells, tissues, and organs. This is done by the use of therapeutic stem cells lines, the production of artificial organs, and tissue engineering.
According to the report, one driver in the market is increased demand for monoclonal antibodies. A monoclonal antibody is a type of protein which is developed in laboratory for binding to substances in the body such as cancer cells. It binds to only one kind of substance so at present there are many kinds of monoclonal antibodies which are used as therapeutic agents such as treatment of different types of cancer. They are either used alone or in conjugation with drugs, radioactive substances or toxins to kill the diseased cells.
– GE Healthcare
– Merck Millipore
– Thermo Fisher Scientific
Other prominent vendors
– Cobra Biologics
– Molecular Devices
– WuXi Biologics
Key Topics Covered:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
PART 05: Market landscape
PART 06: Market segmentation by product
PART 07: Geographical segmentation
PART 08: Decision framework
PART 09: Drivers and challenges
PART 10: Market trends
PART 11: Vendor landscape
PART 12: Key vendor analysis
PART 13: Appendix
For more information about this report visit https://www.researchandmarkets.com/research/7vn85z/global_cell_line